AIM: To investigate whether results of [F-18]-fluorodeoxy-d-glucose (FDG) positron emission tomography (PET) of esophageal cancer (EC) before and after neoadjuvant radio-chemotherapy correlate with histopathology after esophageal resection. METHODS: Twenty consecutive patients with EC without distant metastases were examined twice with 18F-FDG-PET during primary staging and after neoadjuvant radio-chemotherapy. FDG standardised uptake values (SUV) were correlated with the histopathological findings (percentage of viable tumour cells, tumour regression grade 1-5). RESULTS: Regression analysis revealed a slight (not significant) positive correlation between SUV(pre) (R=0.41, p=0.08) and SUV(post) (R=0.37, p=0.11) and the percentage of viable tumour cells in the resectate. Although all patients showed a significant decrease in SUV after radio-chemotherapy (p < 0.01) the percentual decrease of the SUV after therapy (DeltaSUV%) did not significantly differ between the TRG-groups. In 12 of 20 patients (60%), therapy-induced esophagitis was detected in post-therapeutic PET images. CONCLUSION: In EC, a higher pre-therapeutic SUV might be correlated with a higher fraction of vital tumour cells remaining after radio-chemotherapy. Applying the neoadjuvant therapy protocol and the study design used in this examination, there is no correlation between decrease in SUV and histopathology.
AIM: To investigate whether results of [F-18]-fluorodeoxy-d-glucose (FDG) positron emission tomography (PET) of esophageal cancer (EC) before and after neoadjuvant radio-chemotherapy correlate with histopathology after esophageal resection. METHODS: Twenty consecutive patients with EC without distant metastases were examined twice with 18F-FDG-PET during primary staging and after neoadjuvant radio-chemotherapy. FDG standardised uptake values (SUV) were correlated with the histopathological findings (percentage of viable tumour cells, tumour regression grade 1-5). RESULTS: Regression analysis revealed a slight (not significant) positive correlation between SUV(pre) (R=0.41, p=0.08) and SUV(post) (R=0.37, p=0.11) and the percentage of viable tumour cells in the resectate. Although all patients showed a significant decrease in SUV after radio-chemotherapy (p < 0.01) the percentual decrease of the SUV after therapy (DeltaSUV%) did not significantly differ between the TRG-groups. In 12 of 20 patients (60%), therapy-induced esophagitis was detected in post-therapeutic PET images. CONCLUSION: In EC, a higher pre-therapeutic SUV might be correlated with a higher fraction of vital tumour cells remaining after radio-chemotherapy. Applying the neoadjuvant therapy protocol and the study design used in this examination, there is no correlation between decrease in SUV and histopathology.
Authors: Joerg Theisen; Bernd Krause; Christian Peschel; Roland Schmid; Hans Geinitz; Helmut Friess Journal: World J Gastrointest Surg Date: 2009-11-30
Authors: Eugene Y Chang; Xin Li; Michael Jerosch-Herold; Ryan A Priest; C Kristian Enestvedt; Jingang Xu; Charles S Springer; Blair A Jobe Journal: J Gastrointest Surg Date: 2007-09-01 Impact factor: 3.452
Authors: Johannes B Roedl; Elkan F Halpern; Rivka R Colen; Dushyant V Sahani; Alan J Fischman; Michael A Blake Journal: Mol Imaging Biol Date: 2008-09-04 Impact factor: 3.488
Authors: R S Gillies; M R Middleton; C Blesing; K Patel; N Warner; R E K Marshall; N D Maynard; K M Bradley; F V Gleeson Journal: Eur Radiol Date: 2012-05-05 Impact factor: 5.315
Authors: C M Gillham; J A Lucey; M Keogan; G J Duffy; V Malik; A A Raouf; K O'byrne; D Hollywood; C Muldoon; J V Reynolds Journal: Br J Cancer Date: 2006-10-03 Impact factor: 7.640